Literature DB >> 12560463

Accurate molecular detection of melanoma nodal metastases: an assessment of multimarker assay specificity, sensitivity, and detection rate.

V Davids1, S H Kidson, G S Hanekom.   

Abstract

BACKGROUND: The application of lymphoscintigraphy followed by sentinel lymph node (SN) biopsy to patients with primary melanoma has revolutionised the ability to identify accurately, yet conservatively, those patients who harbour occult nodal metastases. The molecular detection of SN micrometastases facilitates the cost effective analysis of the entire SN using multiple markers. Currently, a lack of marker specificity is the main barrier preventing the molecular evaluation of SN tissue from becoming clinically applicable. AIMS: To develop a reproducible multimarker reverse transcription-polymerase chain reaction (RT-PCR) assay, with the emphasis on achieving high specificity for the accurate detection of melanoma metastases in nodal tissue.
METHODS: Three pigment cell specific (PCS) markers-tyrosinase, Pmel-17, and MART-1-and one cancer testis antigen (CTA)-MAGE-3-were selected for use in a multimarker RT-PCR assay. The conditions for this assay were optimised.
RESULTS: High specificity was achievable for each marker by optimising the PCR cycle number such that unwanted transcripts (that is, illegitimate transcripts and/or specific transcripts from other low abundance nodal cell types) remained undetectable in appropriate controls (normal visceral nodes). Tyrosinase was 100% specific at 40 PCR cycles, MAGE-3 and MART-1 at 35 PCR cycles, and Pmel-17 at 30 PCR cycles. Tyrosinase proved to be the most sensitive marker, detecting 10 melanoma cells in 0.1 g of nodal tissue.
CONCLUSIONS: Excellent reproducibility of the entire nodal processing and RT-PCR protocol for the detection of very low numbers of melanoma cells in nodal tissue was shown, although there is a risk of false positives using the PCS markers alone, because of an approximate 4-8.5% incidence rate of nodal nevi in melanoma draining SNs (these nevi being absent in all other normal nodes). MAGE-3 was shown to be the only marker that is not expressed by melanocytes. However, because not all melanomas express MAGE-3, it is recommended that more emphasis should be placed on the development of a panel of CTA markers to ensure a zero false positive rate and to provide optimum detection.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12560463      PMCID: PMC1187289          DOI: 10.1136/mp.56.1.43

Source DB:  PubMed          Journal:  Mol Pathol        ISSN: 1366-8714


  49 in total

1.  Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.

Authors:  K Staveley-O'Carroll; E Sotomayor; J Montgomery; I Borrello; L Hwang; S Fein; D Pardoll; H Levitsky
Journal:  Proc Natl Acad Sci U S A       Date:  1998-02-03       Impact factor: 11.205

2.  Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo.

Authors:  J N Cormier; Y M Hijazi; A Abati; P Fetsch; M Bettinotti; S M Steinberg; S A Rosenberg; F M Marincola
Journal:  Int J Cancer       Date:  1998-02-09       Impact factor: 7.396

3.  Melanoma-associated antigens as messenger RNA detection markers for melanoma.

Authors:  T Sarantou; D D Chi; D A Garrison; A J Conrad; P Schmid; D L Morton; D S Hoon
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 4.  Ultra-late recurrence (15 years or longer) of cutaneous melanoma.

Authors:  H Tsao; A B Cosimi; A J Sober
Journal:  Cancer       Date:  1997-06-15       Impact factor: 6.860

5.  Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.

Authors:  T J de Vries; A Fourkour; T Wobbes; G Verkroost; D J Ruiter; G N van Muijen
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

6.  Prognostic models in melanoma.

Authors:  A C Halpern; L M Schuchter
Journal:  Semin Oncol       Date:  1997-02       Impact factor: 4.929

7.  Nodal nevi and cutaneous melanomas.

Authors:  K F Carson; D R Wen; P X Li; A M Lana; C Bailly; D L Morton; A J Cochran
Journal:  Am J Surg Pathol       Date:  1996-07       Impact factor: 6.394

8.  Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma.

Authors:  J E Gershenwald; M I Colome; J E Lee; P F Mansfield; C Tseng; J J Lee; C M Balch; M I Ross
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

9.  Lymph node micrometastases of cutaneous melanoma: increased sensitivity of molecular diagnosis in comparison to immunohistochemistry.

Authors:  H J Blaheta; B Schittek; H Breuninger; E Maczey; S Kroeber; K Sotlar; U Ellwanger; M H Thelen; G Rassner; B Bültmann; C Garbe
Journal:  Int J Cancer       Date:  1998-08-21       Impact factor: 7.396

10.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

View more
  4 in total

1.  An evaluation of molecular markers for improved detection of breast cancer metastases in sentinel nodes.

Authors:  S Abdul-Rasool; S H Kidson; E Panieri; D Dent; K Pillay; G S Hanekom
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

2.  Sentinel lymph node: detection of micrometastases of melanoma in a molecular study.

Authors:  Valeria C Denninghoff; Andrea G Kahn; Jorge Falco; Hector P Curutchet; Boris Elsner
Journal:  Mol Diagn       Date:  2004

3.  Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression.

Authors:  Ashley M Rosa; Nitika Dabas; Diana M Byrnes; Mark S Eller; James M Grichnik
Journal:  J Skin Cancer       Date:  2012-11-12

Review 4.  Issues affecting molecular staging in the management of patients with melanoma.

Authors:  G Palmieri; M Casula; M C Sini; P A Ascierto; A Cossu
Journal:  J Cell Mol Med       Date:  2007 Sep-Oct       Impact factor: 5.310

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.